The U.S. Patent and Trademark Office will be holding its next biotechnology/chemical/pharmaceutical (BCP) customer partnership meeting on September 24, 2018 at the USPTO Headquarters (Alexandria, VA).  The agenda for the meeting is as follows:

• Welcoming and Opening Remarks (10:00 – 10:10 am EDT) – Gary Jones, Daniel Sullivan, and Andrew Wang, Directors, TC1600, USPTO

• Obviousness of Biologics: Identifying the Biggest Challenges (10:10 – 11:00 am) — Carla Mouta-Bellum of Arrigo, Lee, Guttman & Mouta-Bellum LLP

• Exemplary Obviousness Rationales Suggested in KSR (11:00 – 11:50 am) — Lora Driscoll, QAS, TC1600, USPTO

• Lunch (11:50 am – 12:50 pm)

• 112(f)-New Form Paragraphs (12:50 – 1:40 pm) — Marjorie Moran, QAS, TC1600, USPTO

• Requirements for Information Under 37 CFR 1.105 and Responses to Said Requirements (1:40 – 2:40 pm) — Amjad Abraham, SPE, and Shubo (Joe) Zhou, SPE, TC1600, USPTO

• Break (2:40 – 3:00 pm)

• Accidental Infringement: the need for additional limitations in plant utility claims directed to chemical profiles or cultivars (3:00 – 3:50 pm) — Reggie Gaudino, Chief Science Officer, Steep Hill Labs, Inc.

• Closing Remarks (3:50 – 4:00 pm) – Directors, TC1600, USPTO

Additional information regarding the BCP customer partnership meeting, including registration information for those wishing to attend the meeting or register for online participation, can be found here.